Article
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.
Tumori - 1 Aug 2026
Leonetti Alessandro, Callegari Vanessa, Perrone Fabiana, Maglietta Giuseppe, Bordi Paola, Bria Emilio, Vita Emanuele, Gelsomino Francesco, De Giglio Andrea, Gelibter Alain, Siringo Marco, Mazzoni Francesca, Caliman Enrico, Genova Carlo, Barletta Giulia, Bertolini Federica, Guaitoli Giorgia, Passiglia Francesco, Delcuratolo Marco Donatello, Montrone Michele, Oresti Sara, Pasello Giulia, Roca Elisa, Belluomini Lorenzo, Cecere Fabiana Letizia, Guida Annalisa, Manzo Anna, Russo Alessandro, Rastelli Francesca, Bulotta Alessandra, Citarella Fabrizio, Toschi Luca, Zoratto Federica, Cortinovis Diego Luigi, Paoloni Francesco, Follador Alessandro, Carta Annamaria, Camerini Andrea, Salerno Flavio, Silva Rosa Rita, Baldini Editta, Ficorella Corrado, Brighenti Matteo, Santoni Matteo, Malorgio Francesco, Caminiti Caterina, Puntoni Matteo, Tiseo Marcello
Abstract excerpt
IntroductionChemo-immunotherapy is the standard frontline treatment of advanced non-squamous non-small cell lung cancer (nsq-NSCLC). Among oncogenic drivers, KRAS mutation accounts for approximately 25% of lung adenocarcinomas, with p.G12C being the most common variant. This study assessed clinical features and survival outcomes according to KRAS mutation in a real-life population of nsq-NSCLC patients treated...
Read the complete abstract on PubMed